Valneva SE (VALN) Total Non-Current Liabilities (2020 - 2026)

Valneva SE (VALN) posted quarterly Total Non-Current Liabilities of $228.8 million for Q1 2026, little changed year-on-year from $228.5 million in Q1 2025, and up 0.88% on a QoQ basis from $226.8 million in Q4 2025.

Valneva SE (VALN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Valneva SE (VALN) has reported Total Non-Current Liabilities for 7 consecutive years, with $228.8 million the latest figure, recorded in Q1 2026.

  • Quarterly Total Non-Current Liabilities changed 0.15% year-over-year to $228.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $228.8 million (changed 0.15% YoY) and the FY2025 annual result came in at $226.8 million, down 2.38% from the prior year.
  • Total Non-Current Liabilities rose to $228.8 million in Q1 2026 per VALN's latest filing, from $226.8 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for VALN reached as high as $302.8 million in Q1 2022 and fell as low as $126.1 million in Q2 2023.
  • A 5-year average of $200.4 million and a median of $216.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2022 — Total Non-Current Liabilities tumbled 55.31% — and 2024, when it surged 78.49%.
  • Year by year, Total Non-Current Liabilities stood at $141.3 million in 2022, then surged by 39.3% to $196.8 million in 2023, then rose by 18.07% to $232.4 million in 2024, then retreated by 2.38% to $226.8 million in 2025, then grew by 0.88% to $228.8 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $228.8 million, $226.8 million, and $167.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Valneva SE 803.90 Mn 680.66 Mn 5.38 Mn 228.84 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 228.84 Mn
Dec 31, 2025 226.83 Mn
Sep 30, 2025 167.59 Mn
Jun 30, 2025 182.68 Mn
Mar 31, 2025 228.49 Mn
Dec 31, 2024 232.37 Mn
Sep 30, 2024 216.20 Mn
Jun 30, 2024 225.09 Mn
Mar 31, 2024 224.76 Mn
Dec 31, 2023 196.81 Mn
Sep 30, 2023 164.85 Mn
Jun 30, 2023 126.11 Mn
Mar 31, 2023 138.78 Mn
Dec 31, 2022 141.28 Mn
Sep 30, 2022 180.81 Mn
Jun 30, 2022 222.72 Mn
Mar 31, 2022 302.75 Mn
Dec 31, 2021 316.11 Mn
Dec 31, 2020 222.89 Mn